马来酸依那普利联合阿替洛尔治疗慢性心力衰竭的疗效和安全性评价  

Efficacy and Safety of Enalapril Maleate Combined with Atenolol in Treating Chronic Heart Failure

作　　者：薛蕊[1] 苏怀玲[1] 李明[1] 

机构地区：[1]山东省济南市第五人民医院,山东济南250022

出　　处：《中国药业》2016年第15期63-65,共3页China Pharmaceuticals

摘　　要：目的评价马来酸依那普利联合阿替洛尔用于治疗慢性心力衰竭的临床疗效及用药安全性。方法选择2013年12月至2014年12月医院收治并经临床确诊的84例慢性心力衰竭患者,按就诊顺序进行编号并随机分作两组,每组42例,对照组给予马来酸依那普利治疗,治疗组在对照组用药基础上联合阿替洛尔治疗。比较并分析两组患者的临床治疗效果及不良反应发生情况。结果治疗组总有效率为95.24%,明显高于对照组的76.19%(P<0.05)。治疗后,治疗组患者左室舒张末期内径(LVEDd)为(52.46±4.82)mm、左室收缩末期内径(LVESd)为(37.68±4.16)mm,均较治疗前明显降低(P<0.05),且显著低于对照组(P<0.05);左室射血分数(LVEF)为(62.48±5.72)%,较治疗前明显升高(P<0.05),且显著高于对照组(P<0.05)。治疗后,治疗组心率、血压、心功能各项指标均显著优于对照组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论马来酸依那普利联合阿替洛尔治疗慢性心力衰竭可使患者的心功能得到有效改善,且不良反应较少,安全性高。Objective To analyze the clinical efficacy and safety of enalapril maleate combined with atenolol for treating chronic heart failure. Methods 84 cases of clinically diagnosed with chronic heart failure from December 2013 to December 2014were randomly di- vided into two groups, 42 cases in each group. The control group was given enalapril maleate, while the treatment group was added with atenolol. The clinical outcomes and adverse occurrence of the two groups were compared. Results The overall response rate of the observation group was 95.24%, which was significantly higher than 76. 19% of the control group（ P 〈 0. 05）. After treatment, the LVEDd and LVESD of the observation group were （52.46±4.82） mm and （37.68±4. 16） mm, which were significantly lower than pre- treatment and the control group after treatment（P 〈 0.05）; the LVEF of the observation group was （62.48 ±5.72）%, which was sig- nificantly higher than pre-treatment, and the differences were statistically significant（ P 〈 0. 05）. After treatment, the HR, SBP, DBP and SV of the treatment group were significantly better than the control group（ P 〈 0. 05）. The incidence of adverse reactions between the two groups showed no significant difference（ P 〉 0. 05）. Conclusion The effect of enalapril maleate combined with atenolol in the treat- ment of chronic heart failure is significant, and it can improve heart function of the patients with fewer adverse reactions, which is safe.

关 键 词：马来酸依那普利 阿替洛尔 慢性心力衰竭 疗效 安全性 

分 类 号：R969.4[医药卫生—药理学] R972.4[医药卫生—药学]